Antiviral Drugs - Papua New Guinea

The revenue in the Antiviral Drugs market in Papua New Guinea is anticipated to achieve US$2.29m by the year 2024.
It is expected that the revenue will display an annual growth rate (CAGR 2024-2029) of 0.97%, leading to a market volume of US$2.41m by 2029.
When compared globally, United States will generate the highest revenue, amounting to US$30.64bn in 2024.
Despite the increasing global demand for antiviral drugs, Papua New Guinea's limited healthcare infrastructure poses challenges for widespread availability and distribution.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

Antiviral drugs have become increasingly important in the healthcare industry due to the rise of viral infections. Papua New Guinea, a country located in the South Pacific, has seen a development in the Antiviral Drugs market.

Customer preferences: The demand for antiviral drugs in Papua New Guinea has increased due to the rise in viral infections such as HIV, hepatitis, and influenza. The healthcare industry has been focusing on providing better treatment options for these infections, leading to an increase in demand for antiviral drugs.

Trends in the market: The Antiviral Drugs market in Papua New Guinea has been developing due to the increase in the prevalence of viral infections. The healthcare industry has been focusing on developing new and effective antiviral drugs to treat these infections. There has been a shift towards combination therapies that use multiple drugs to treat viral infections, leading to an increase in demand for antiviral drugs.

Local special circumstances: Papua New Guinea has a high prevalence of viral infections, with HIV being a major concern. The healthcare industry has been focusing on providing better treatment options for HIV and other viral infections. The government has been investing in the healthcare industry to improve the quality of healthcare services in the country.

Underlying macroeconomic factors: The Antiviral Drugs market in Papua New Guinea is influenced by the country's economic growth. As the country's economy continues to grow, the healthcare industry is expected to expand, leading to an increase in demand for antiviral drugs. The government's investment in the healthcare industry is also expected to contribute to the growth of the Antiviral Drugs market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.